Yüklüyor......
The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the (V600E)BRAF mutation. Inhibition of downstream MAPK signaling with vemurafenib induces apoptotic cell death mediated by caspase-3, suggesting that addition of a procasp...
Kaydedildi:
| Yayımlandı: | Mol Cancer Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4975653/ https://ncbi.nlm.nih.gov/pubmed/27297867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0025 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|